

## TRANSFORMATIVE THERAPIES TARGETING CANCER

Seattle Genetics is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people's lives. ADCETRIS® (brentuximab vedotin) utilizes the company's industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors.

### ADCETRIS: FDA/EMA APPROVED PRODUCT AND EXPANDING GLOBAL BRAND

- Antibody-drug conjugate that targets CD30, which is expressed in classical Hodgkin lymphoma as well as other types of lymphoma
- Approved in the U.S. for 5 indications including frontline Stage 3 or 4 Hodgkin lymphoma (HL) and relapsed HL; commercially available in 71 countries
- Ongoing phase 3 trials in frontline peripheral T-cell lymphoma with data expected early in 4Q-2018 as well as in combination with the checkpoint inhibitor, nivolumab
- Seattle Genetics commercializes in the U.S. and Canada and Takeda commercializes in the rest of world
- Global sales reached approximately \$640 million in 2017

### QUICK FACTS

**NASDAQ SYMBOL:** SGEN

**EMPLOYEES:** 1,225+ worldwide

**MANAGEMENT:**

Clay Siegall, Ph.D., *President, CEO & Chairman*

Todd Simpson, *CFO*

Roger Dansey, M.D., *CMO*

**HEADQUARTERS / EUROPEAN OFFICE:**

Bothell, WA USA / Zug, Switzerland

**COMMERCIAL PRODUCT:**

ADCETRIS® (brentuximab vedotin)

**1H-2018 AS OF 6/30/18:**

**TOTAL REVENUE:** \$311 million

**R&D EXPENSE:** \$275 million

**CASH:** \$458 million

**SHARES OUTSTANDING:** ~158 million


**WEBSITE:** [www.seattlegenetics.com](http://www.seattlegenetics.com)

### ROBUST PRODUCT PIPELINE: ADCETRIS AND PROGRAMS IN PIVOTAL TRIALS

PROGRAM	TUMOR TYPE	PHASE 1	PHASE 2	PHASE 3	PARTNER
ADCETRIS (Brentuximab Vedotin)	Frontline peripheral T-cell lymphoma	ECHELON-2 data expected in 2018			
	Relapsed Hodgkin lymphoma (HL)	CheckMate 812: combination with nivolumab			
	Relapsed non-Hodgkin lymphoma	CheckMate 436: combination with nivolumab			
	Frontline HL (patients 60+)	Combination with nivolumab			
	Second-line HL	Combination with nivolumab			
	Relapsed HL (pediatrics)	CheckMate 744: combination with nivolumab			
Enfortumab Vedotin	Metastatic urothelial cancer	EV-301: post-checkpoint inhibitor			
		EV-201: post-checkpoint inhibitor Pivotal			
	First-line and second-line urothelial cancer	EV-103: combination w/ checkpoint inhibitor			
Tucatinib	HER2+ metastatic breast cancer	HER2CLIMB		Pivotal	
Tisotumab Vedotin	Recurrent/metastatic cervical cancer	innovaTV 204		Pivotal	
	Solid tumors	innovaTV 207			

Seattle Genetics is also advancing several earlier-stage proprietary targeted therapies in clinical and preclinical development not shown on the pipeline chart above. Visit our website for more details.

# ADVANCING TARGETED THERAPIES FOR CANCER: ADC TECHNOLOGY AND BEYOND



Various combinations of these novel modalities are likely to be the future of treatment in oncology

## POTENTIAL TO IMPROVE PATIENT OUTCOMES THROUGH MULTIPLE APPROACHES TO TARGETED THERAPIES

We are developing highly-specific targeted therapies that provide multiple approaches for the treatment of cancer. These include agents that are directed toward receptors on the outside of cells, the signaling pathways within the cell, and the activation of immune cells. These agents may be used as single agents, or as part of combination regimens.

### TARGETING OUTSIDE OF THE CELL

Our antibody-drug conjugate technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer.

In our ADCs, stable linkers attach a potent synthetic cell-killing (cytotoxic) agent to an antibody. The antibody is targeted against a specific tumor-associated receptor on cancer cell surfaces. Our linker

systems release the cytotoxic agent once inside the targeted cells. By targeting specific tumor-associated receptors on the surface of cancer cells, ADCs have the potential to spare non-targeted cells and reduce toxic side effects resulting in better outcomes for patients.

Our ADC technology is employed in our approved product, ADCETRIS, and three other programs in pivotal trials, as well as in several earlier-stage candidates.

### TARGETING PATHWAYS INSIDE THE CELL

Certain signaling pathways in the cell are known to be involved in initiation and progression of cancer. For instance, the kinase signaling pathway has been shown to drive many aspects of cancer tumor biology including survival, motility and evasion of antitumor immune response. We are currently conducting a pivotal trial of an oral tyrosine kinase inhibitor, tucatinib, for patients with an aggressive type of breast cancer.

## EXTENDING OUR OPPORTUNITIES THROUGH ADC TECHNOLOGY COLLABORATIONS

Beyond the broad internal development of our ADCs, we have entered into collaborations with a number of biotechnology and pharmaceutical companies. These licensing agreements have generated more than \$400 million to date and have the potential to generate approximately \$2.5 billion in potential future milestones as well as royalties on net sales of any approved products. AbbVie, GlaxoSmithKline and Roche have agents from our collaborations currently in pivotal trials.

## ACTIVATING IMMUNE CELLS

Immunogenic cell death induced by ADCs can result in the stimulation and recruitment of an immune response toward cancer. We believe these properties could make ADCs a preferred partner for immuno-oncology agents, such as checkpoint inhibitors. We are currently conducting several clinical trials combining ADCs with checkpoint inhibitors.

## CONTINUING TO ADVANCE OTHER APPROACHES

We are conducting phase 1 trials of several novel agents. For example, we have a phase 1 trial evaluating SEA-BCMA, an antibody empowered using our proprietary Sugar Engineered Antibody (SEA) technology designed to enhance antibody dependent cellular cytotoxicity. The target of SEA-BCMA, the cell surface protein B-cell maturation antigen (BCMA), is broadly expressed on malignant plasma cells in multiple myeloma. SEA-BCMA has demonstrated promising antitumor activity in preclinical studies.



### Investors:

Peggy Pinkston  
425.527.4160

[Investors@seagen.com](mailto:Investors@seagen.com)

### Media:

Monique Greer  
425.527.4641

[Media@seagen.com](mailto:Media@seagen.com)